Roux, Sophie

Professeure, Faculté de médecine et des sciences de la santé
FMSS Département de médecine

Coordonnées

Courriel


819-821-8000, poste 15261

Diplômes

(2002) RANK and RANKL expression in malignant osteolysis. Post-doctorat (Formation post-doctorale). Université de Paris XI (Paris-Sud).

(1997) Soluble factors involved in human osteoclast differentiation. Doctorat (Doctorat en sciences-Ph.D.). Université de Paris VII (Denis Diderot).

(1994) Angiotropic large cell lymphoma. Doctorat (Doctorat en médecine - M.D.). Université de Paris VI (P & M Curie).

(1993) Diplôme (Diplôme d'Université (DU)). Université de Paris VII (Denis Diderot).

(1993) Osteoclast differentiation and giant cell tumors of bone. Maîtrise avec mémoire (Diplôme d'Études Approfondies (DEA)). Université de Paris VII (Denis Diderot).

(1991) Diplôme (Immunologie Générale et Immunotechnologie). Institut Pasteur.

(1989) Equivalent à la maîtrise (Maîtrise de Biochimie). Université de Paris VII (Denis Diderot).

(1987) Diplôme (Internat des Hôpitaux de Paris - M.D.).

(1981) Diplôme (Concours 1ère année médecine). Université de Paris VI (P & M Curie).

Titres de compétence

Certified Specialist of the Province of Quebec (CSPQ). Collège des médecins du Québec.

MCU-PH (Maître de Conférences des Universités-praticien Hospitalier).

Researcher.

Présentation

Sujets de recherche

Maladies du tissu osseux, Signalisation cellulaire, Tissu osseux.

Disciplines de recherche

Biologie cellulaire, Rhumatologie.

Mots-clés

Apoptose, Autophagie, Épissage alternatif, Érosions dans la Polyarthrite rhumatoïde, Maladie de Paget, micro ARNs, Ostéoclaste, Ostéoporose et Fractures de fragilité, p62/sequestosome, Physiologie osseuse, Résorption osseuse, Signalisation RANKL.

Intérêts de recherche

- Biologie de l'ostéoclaste : Ostéoclaste humain: modèle in vitro; étude de la la formation, l'activation et l'apoptose des ostéoclastes; résorption osseuse; - p62 et voies de signalisation de RANKL; - Épissage alternatif; - micro ARNs; - autophagie - maladies osseuses: Maladie de Paget, Ostéoporose - destruction osseuse dans la polyarthrite rhumatoïde

Recherche clinique

Oui

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Prix et distinctions

  • (2015) Clinical Research Scholars – Senior. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
  • (2011) Clinical Research Scholars – Junior 2. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
  • (2007) Clinical Research Scholars - Junior 1. Fonds de recherche du Québec - Santé (FRQS). (Distinction).
  • Basic research award- Procter & Gamble. (Prix / Récompense).
  • G. Plante's Career honorific award presentation. Université de Sherbrooke. (Distinction).

Publications

Articles de revue

  • Roux S. (2015). [New advances in myltiple myeloma bone disease and therapeutic applications]. Reflexions Rhumatologiques, (Article sous presse).
  • Roux S. (2015). [Bone and joints in hematological malignancies (Myeloma excluded)]. Encyclopédie Médico-Chirurgicale (EMC Rhumatologie-Orthopédie), 10(1), 1-9. (Article publié).
  • Klinck R, Laberge G, Bisson M, McManus S, Michou L, Brown JP, Roux S. (2014). Alternative splicing in osteoclasts and Paget’s disease of bone. BMC- Medical Genetics, 15(1), 98. (Article publié).
  • Roux S, Cabana F, Carrier N, Beaulieu M, April PM, Beaulieu M, Boire G. (2014). The World Health Organisation Fracture Risk Assessment tool (FRAX® without BMD) underestimates incident and recurrent fractures in consecutive patients with fragility fractures. J Clin Endocrinol Metab, 99(7), 2400-8. (Article publié).
  • Bissonnette L , April PM , Dumais R , Boire G , Roux S. (2013). Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: A case report. Bone, 56(2), (Article publié).
  • Chamoux E , McManus S , Laberge G , Bisson M , Roux S. (2013). Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-kappaB in human osteoclasts. Biochimica Biophysica Acta - Molecular Basis of Disease, 1832(3), (Article publié).
  • Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G. (2013). Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach. J Rheumatol, 40(5), (Article publié).
  • Fong D , Bisson M , Laberge G , McManus S , Grenier G , Faucheux N , Roux S. (2013). Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro. Cellular Signalling, 25(4), (Article publié).
  • Yue L, Durand M , Lebeau Jacob MC , Hogan P , McManus S , Roux S , de Brum-Fernandes AJ. (2012). Prostaglandin D(2) induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone, 51(3), (Article publié).
  • McManus S , Chamoux E , Bisson M , Roux S. (2012). Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. Apoptosis, 17(2), (Article publié).
  • McManus S, Roux S. (2012). The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J Mol Signal, 7(1), (Article publié).
  • Roux S. (2011). [The RANK-RANKL-OPG axis in rheumatoid arthritis]. Reflexions Rhumatologiques, 15(143), 10-13. (Article publié).
  • Roux S. (2011). [The RANKL-RANK pathway: an update]. Reflexions Rhumatologiques, 15(143), 4-9. (Article publié).
  • Trensz F , Haroun S , Drouin G , Bergeron E , Penton CM , Montanaro F , Roux S , Faucheux N , Grenier G. (2011). BMP-9-induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment. J Bone Miner Res, 26(6), (Article publié).
  • Bergeron E , Senta H , Lauzon MA , Roux S , Grenier G , Faucheux N. (2010). Effect of functionalized polycaprolactone on the behaviour of murine preosteoblasts. Biomaterials, 31(25), (Article publié).
  • Chamoux E, Bisson M , Payet MD , Roux S. (2010). TRPV-5 mediates a receptor activator of NF-kappaB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption. J Biol Chem, 285(33), (Article publié).
  • Roux S, Mariette X. (2010). RANK and RANKL expression in giant-cell tumour of bone. Lancet Oncol, 11(6), (Article publié).
  • Roux S. (2010). New treatment targets in osteoporosis. Joint Bone Spine, 77(3), (Article publié).
  • Michou L, Chamoux E , Couture J , Morissette J , Brown JP , Roux S. (2010). Gene expression profile in osteoclasts from patients with Paget's disease of bone. Bone, 46(3), (Article publié).
  • Gallant MA , Chamoux E , Bisson M , Wolsen C , Parent JL , Roux S , de Brum-Fernandes AJ. (2010). Increased concentrations of prostaglandin D2 during post-fracture bone remodeling. J Rheumatol, 37(3), (Article publié).

Chapitres de livre

  • McManus, S Bissonette, L Roux, S. (2012). Osteoclast biology in Paget's disease of bone. Osteoclasts: Morphology, Functions and Clinical Implications (NOVA Science Publishers, p 77-94). Nova Science Publishers. (Article publié).
  • Roux S, Philippin G, Vieillard MH. (2012). Malignant Bone Diseases. Textbook on Rheumatic Diseases (p 808-833). BMJ Editions. (Article publié).

Articles de journaux

  • (2007). Those too brittle bones. The Record. 12.

Rapports

  • Roux, S. (2014). Meeting Report: ASBMR 2014.
  • Roux, S. (2013). Meeting Report: ASBMR 2013.
  • Roux S. (2012). ASBMR 2012, Minneapolis. 20 p.
  • Roux S. (2011). ASBMR 2011, San Diego. 20 p.
  • Roux S. (2010). ASBMR 2010, Toronto. 20 p.

Lignes directrices en matière de soins cliniques

  • S. Roux, G. Boire, F. Cabana. (2011). Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis (OPTIMUS).

Articles de conférence

  • McManus S, Bisson M, Chamberland R, Roy M, Nazari S, Roux S. (2015). Autophagy and Phospho-Inositide Dependent Kinase 1 (PDK1) -Related Kinome in Pagetic Osteoclasts. J Bone Miner Res 2015, (Article publié).
  • Rodrigue L, Cabana F, Carrier N, Sale J, Roux S, Boire G. (2015). Characteristics of Patients Classified as Low or Moderate Risk Based on Fracture Risk Assessment (FRAX) After a Fragility Fracture. J Bone Miner Res 2015, (Article publié).
  • Gionet-Landry N, Cabana F, Gaboury I, Boire G, Roux S, Carrier N, Beaulieu MC. (2015). Why patients still untreated 1 year after a Fragility Fracture refuse an intervention to treat osteoporosis?. J Bone Miner Res 2015, (Article publié).
  • April PM, Boire G, Cabana F, Beaulieu MC, Roux S. (2015). Up to half of first Fragility Fractures (FF), and a third of recurrent FF, occurin patients with low or moderate estimated FRAX® 10-year fracture risk: resultsfrom the OPTIMUS initiative. 3rd World Congress on Controversies, Debate & Consensus in Bone, Muscle & Joint Diseases (BMJD). (Article publié).
  • Cabana F, Beaulieu MC, Carrier N, Roux S, Boire G. (2014). How long does the therapeutic window ofopportunity last after a fragility fracture?. J Bone Miner Res, (Article publié).
  • Beaulieu MC, Cabana F, Beaulieu M, Carrier N, Roux S, Boire G. (2014). Improving treatment adherence through rapid integrated interdisciplinary intervention after a fragility fracture: the OPTIMUS initiative. Canadian Rheumatology Association (CRA). (Article accepté).
  • Cabana F, Péladeau M, Carrier N, Beaulieu MC, Beaulieu M, Roux S, Boire G. (2014). Which patients with low trauma ankle fractures are at risk for subsequent fragility fractures in the Optimus cohort?. Canadian Rheumatology Association (CRA). (Article accepté).
  • Beaulieu MC, Cabana F, Beaulieu M, Carrier N, Roux S, Boire G. (2013). Improving Adherence Through Rapid Integrated Interdisciplinary Intervention After A Fragility Fracture. NAPCRG 41st Annual Meeting. (Article publié).
  • McManus S, Laberge G, Bisson M, Roux S. (2013). PDK1/Akt pathway is involved in osteoclast signaling in Paget’s disease of bone. J Bone Miner Res 2013, 29 (suppl 1), S273. (Article publié).
  • Cabana F, Carrier N, Beaulieu MC, Beaulieu M, Roux S, Boire G. (2013). Which Patients with Ankle Fractures Are at Risk for Recurrent Fragility Fractures? Results from the OPTIMUS Initiative. J Bone Miner Res 2013, 29 (suppl 1), S436. (Article publié).
  • April PM, Cabana F, Beaulieu MC, Beaulieu M, Roux S, Boire G. (2013). Up to half of first fragility fractures (FF), and a third of recurrent FF, occur in patients with low or moderate estimated FRAX® 10-year fracture risk: results from the OPTIMUS initiative. Ann Rheum Dis 2013; 72 (suppl 2), (Article publié).
  • April PM, Poirier N, Roux S, Beaulieu MC, Beaulieu M, Cabana F, Boire G. (2012). Estimated Frax® 10-Year Fracture Risk at the Time of Incident Fracture and Upon Refracture: Results from the OPTIMUS Initiative. J Bone Miner Res 2012, 27 (suppl 1), S115. (Article publié).
  • Beaulieu MC, Roux S, Poirier N, Beaulieu M, Cabana F, Boire G. (2012). Management of fragility fractures: impact of the OPTIMUS initiative on family physicians. J Bone Miner Res 2012, 27 (suppl 1), S109. (Article publié).
  • de Brum-Fernandes AJ, Yue L, Roux S, McManus S. (2012). Prostaglandin D2 Induces Apoptosis of Human Osteoclasts Through the Activation of Akt and ERK Signaling Pathways. J Bone Miner Res 2012, 27 (suppl 1), S414. (Article publié).
  • Beaulieu MC, Cabana F, Beaulieu M, Roux S, Boire G. (2012). Management of fragility fractures: impact of the OPTIMUS initiative on family physicians. 1st FFN (Fracture Fragility Network) Global Congress. (Article publié).
  • Cabana F, Roux S, Beaulieu MC, Beaulieu M, Boire G. (2012). Incidence of subsequent fractures according to site of initial non-vertebral fractures and treatment status (OPTIMUS). Ann Rheum Dis 2012; 71 (suppl 3), 589. (Article publié).
  • Beaulieu MC, Cabana F, Beaulieu M, Roux S, Boire G. (2012). Management of fragility fractures: impact of the optimus initiative on family physicians. Ann Rheum Dis 2012; 71 (suppl 3), 596. (Article publié).
  • Boulay-Jean S, McManus S, Roux S. (2012). [Role of the p62P392L mutation in the activation of NFATc1 in paretic osteoclasts]. Scientific meeting FMSS, 41st Edition, Sherbrooke University. (Article publié).
  • Cabana F, Beaulieu M, Lambert D, Cote P, Vaillancourt M, Beaulieu M, Roux S, Boire G. (2011). Incidence of Subsequent Fractures According to Age and Site of Initial Non-Vertebral Fractures (OPTIMUS). J Bone Miner Res 2011; 26 (suppl 1), S484. (Article publié).
  • Chamoux E, Bisson M, Brown J, Roux S. (2010). p62, PKCzeta and NF-kappaB Signaling in Human Osteoclasts: a Link With Paget's Disease of Bone. J Bone Miner Res 2010, 25 (suppl 1), S185. (Article publié).

Autres contributions

Cours enseignés

  • Onco-Rhumatologie. DIU. (2012-12-03).
  • Course on Rheumatic Diseases. EULAR Online. (2007-10-17).
  • Pathologies Osseuses Médicales. DIU. (2006-04-03).
  • Unité de l'appareil locomoteur. MDP161. (2003-04-08). Université de Sherbrooke. Canada.
  • Endocrinologie moléculaire. BCM 606. (2003-01-01). Université de Sherbrooke. Canada.
  • Immunologie clinique. IML 710. (2002-04-30). Université de Sherbrooke. Canada.

Présentations

  • (2014). [Osteoclasts in bone diseases and rheumatoid arthritis]. Career honorific award presentation Annual scientific meeting FMSS. Sherbrooke.
  • (2014). [Oversuppression of bone turnover with anti-catabolic agents]. 45e Conférence laurentienne de rhumatologie. Mont-Tremblant.
  • (2013). p62-related signaling and autophagy in pagetic osteoclasts. Cell Biology Seminar. Toronto.
  • (2012). [New targets in malignant osteolysis]. Francophones d’Oncologie Médicale. Lille.
  • (2010). Identification of specific RNA isoforms of pagetic osteoclasts in Paget’s disease of bone. 3rd Annual Canadian Human Genetics Conference. St-Sauveur.